Inhibitors of the viral nucleoprotein polymerase co factor interaction for human RSV and MPV therapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI127009-01
Agency Tracking Number: R41AI127009
Amount: $584,808.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA15-270
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-01
Award End Date (Contract End Date): 2019-07-31
Small Business Information
1 INNOVATION DR, Worcester, MA, 01605-4307
DUNS: 158864715
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DONALD MOIR
 (508) 757-2800
 dmoir@microbiotix.com
Business Contact
 TERRY BOWLIN
Phone: (508) 757-2800
Email: tbowlin@microbiotix.com
Research Institution
 WASHINGTON UNIVERSITY
 Campus Box 1054
1 Brookings Drive
SAINT LOUIS, MO, 63130-4862
 Nonprofit college or university
Abstract
Human respiratory syncytial virus hRSV and human metapneumovirus hMPV are non segmented negative strand viruses NNSV and are the leading causes of acute respiratory tract infections in infants worldwide In addition hRSV is a significant cause of disease in elderly populations and can often be fatal for patients with compromised immune systems Currently no vaccines are available and existing therapeutics e g ribavirin immunoglobulin or anti hRSV monoclonal Synagis exhibit poor efficacy and present safety concerns The development of safer more effective therapeutics is a major unmet medical need The goal of this project is to address this need by discovering and developing inhibitors of hRSV and hMPV RNA synthesis for therapeutic use by targeting the interaction between the viral nucleoprotein N and the viral P protein a cofactor for the viral polymerase L This interaction is critical for viral RNA synthesis in cells infected with NNSVs an L N complex is required for replication and P mediates interactions between L and the N RNA template The strategy is to build and apply biochemical screens for inhibitors of the hRSV and hMPV N P interaction based on fluorescence polarization This approach is based on a successful anti Ebola virus screening effort carried out by this team to identify inhibitors of the interaction between the Ebola nucleoprotein eNP and the Ebola P protein equivalent known as eVP Development and application of a primary fluorescence polarization assay FPA followed by secondary assays including a counter screen FPA based on an unrelated interaction resulted in the discovery of six specific eVP eNP interaction inhibitors with IC values ranging from M to M Two of these compounds inhibited Ebola RNA synthesis in a cell based assay known as a minigenome replication assay In Phase I these efforts will be extended to target this conserved viral interaction by focusing on hRSV and hMPV which are of broad clinical importance Primary FPA screens for inhibitors of the hRSV and hMPV N protein interactions with fluorophore labeled peptides from the corresponding P proteins will be developed In addition biochemical e g biolayer interferometry BLI and cellular e g split luciferase secondary assays with orthogonal read outs will be constructed to validate initial hits and to assess cellular permeability and mechanism of action The primary and secondary assays will be applied to andgt diverse compounds Confirmed potent selective inhibitors will be validated by determining their ability to inhibit infectious viral assays and by ensuring that they are not cytotoxic In vitro ADME assays and preliminary SAR will prioritize analogs for further optimization Strengths of this proposal include the productive collaborative research team highly sensitive homogeneous FPA screens FPA counter screens to rapidly recognize and eliminate false positives potential to identify broad inhibitors targeting hRSV and hMPV and cellular assays to establish the target specific function In Phase II priority validated inhibitors will be chemically optimized into lead compounds for efficacy and toxicity testing in animal models Narrative Human respiratory syncytial virus hRSV and human metapneumovirus hMPV are the leading causes of acute respiratory tract infections in infants worldwide Currently no vaccines are available and existing therapeutics exhibit poor efficacy and present safety concerns The goal of this proposal is to discover and develop novel safe inhibitors of hRSV and hMPV RNA synthesis for therapeutic use by targeting the interaction between the viral nucleoprotein N and the viral P protein a cofactor for the viral polymerase L This interaction is critical for viral RNA synthesis and viral replication

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government